• Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24844664


    Sources:
    DTC

  • Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17980607


    Sources:
    DTC

  • Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20855208


    Sources:
    DTC

  • Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19110422


    Sources:
    DTC

  • Interaction Score: 1.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Approval Status Phase II
    Response Type predicted – sensitive
    Indication/Tumor Type triple-receptor negative breast cancer

  • Interaction Score: 1.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name perifosine, KRX-0401
    Novel drug target Novel Target
    Indication/Tumor Type ovarian clear cell carcinoma

  • Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Evidence Type Actionable
    Approval Status Phase I

  • Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17603540


    Sources:
    DTC

  • Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Novel Target
    Trial Name RX-0201 ,Archexin
    combination therapy Everolimus + RX-0201

    PMIDs:
    None found


  • Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type no benefit

  • Interaction Score: 0.86

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Indication/Tumor Type ovarian cancer

  • Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22026410


    Sources:
    DTC

  • Interaction Score: 0.56

    Interaction Types & Directionality:
    allosteric modulator
    inhibitory allosteric modulator (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    combination therapy MK2206 + Vemurafenib
    Indication/Tumor Type melanoma

  • Interaction Score: 0.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20822912


    Sources:
    DTC

  • Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Interaction Score: 0.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor

    PMIDs:
    None found


  • Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23390247


    Sources:
    JAX-CKB

  • Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Novel drug target Novel Target

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    allosteric modulator
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor

    PMIDs:
    None found


  • Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17911251


    Sources:
    DTC

  • Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25675144


    Sources:
    DTC

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16767085


    Sources:
    DTC

  • Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19465931


    Sources:
    DTC

  • Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22148921


    Sources:
    DTC

  • Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20726569


    Sources:
    DTC

  • Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21440338


    Sources:
    DTC

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    27016228


    Sources:
    JAX-CKB

  • Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24265155


    Sources:
    CIViC

  • Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy MK2206 + Vemurafenib
    Evidence Type Actionable

    PMIDs:
    24265152


    Sources:
    JAX-CKB CIViC

  • Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18559524


    Sources:
    DTC

  • Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26372073


    Sources:
    DTC

  • Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10187855


    Sources:
    NCI

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20166697


    Sources:
    DTC

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type resistant

    PMIDs:
    27604488


    Sources:
    JAX-CKB

  • Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:


    Sources:
    DTC

  • Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    27604488


    Sources:
    JAX-CKB

  • Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


  • Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


  • Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase Ib/II
    Response Type sensitive

    PMIDs:
    None found


  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    25714871


    Sources:
    JAX-CKB

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17472962


    Sources:
    DTC

  • Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    25714871


    Sources:
    JAX-CKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18855532


    Sources:
    PharmGKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type predicted – sensitive
    combination therapy Doxorubicin + Sirolimus
    Evidence Type Actionable

    PMIDs:
    18708578


    Sources:
    JAX-CKB

  • Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Perifosine
    Indication/Tumor Type ovarian clear cell carcinoma
    Response Type predicted – sensitive


    Sources:
    JAX-CKB PharmGKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22901187


    Sources:
    PharmGKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lymphoma
    Response Type decreased response
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    18708578


    Sources:
    JAX-CKB

  • Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – resistant

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – resistant

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ipatasertib + Paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB